Johnson & Johnson Consumer Inc. announced today that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a global leader in dermocosmetics.
The acquisition will include NeoStrata’s affiliates and parent company TriStrata, Incorporated, a privately-held company. Financial terms were not disclosed.
NeoStrata, based in Princeton, N.J., has a history of innovation that includes breakthrough research in Alpha hydroxy acids, which have become a standard among anti-aging technologies in the beauty category. The Company develops and markets a range of clinically-proven, dermatologist-developed, skin care products that meet the needs of every skin type.
“Drs. Ruey Yu and Eugene Van Scott formed NeoStrata in 1988 and continue to make significant contributions to the science of skincare. NeoStrata’s legacy in dermocosmetics will complement our global Consumer portfolio and enable us to deliver advanced skin care brands to consumers around the world,” said Jorge Mesquita, Worldwide Chairman, Consumer, Johnson & Johnson. “NeoStrata and Johnson & Johnson share a strong history of innovation and together we will work to discover important new skin care solutions grounded in deep human insights and compelling science. We look forward to working closely with NeoStrata’s distributors around the world and having their outstanding team of employees join Johnson & Johnson Consumer later this year.”
The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions and expected to close in the first half of 2016.
Source: Johnson & Johnson
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.
